Fluoro-ss-Carboline Compounds for Wnt-Driven Bone Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for treating bone disorders and fractures, such as osteoporosis and non-union fractures, primarily focus on inhibiting bone resorption without effectively promoting new bone formation, leading to inadequate bone density gains and poor healing in large bone defects.
Innovation Solution
Development of fluoro-ss-carboline compounds that modulate the Wnt/LRP and/or BMP signaling pathways to promote bone formation, either systemically or locally, and their use in medical devices with osteoconductive agents for targeted bone growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiresorptive therapy is used to stop bone resorption, then bone loss is reduced, but bone density gain is limited (less than 6% in first year, 9.4% over three years)
Solution Approach 1:
Instead of focusing on stopping bone resorption (the conventional approach), the invention inverts the strategy by directly stimulating bone formation through Wnt pathway activation. The compound Sclerostin antibody or FPP analogs bind to sclerostin to inhibit its antagonistic effect on Wnt signaling, thereby promoting osteoblast activity and new bone formation rather than merely preventing bone loss.
Solution Approach 2:
The invention changes the fundamental parameter of bone metabolism from net bone loss prevention to active bone formation stimulation. By modulating the Wnt signaling pathway intensity through sclerostin inhibition, the therapy shifts the bone remodeling balance toward formation, achieving superior bone density gains compared to antiresorptive monotherapy.
2Reliability
If current therapies focus on inhibiting bone resorption, then osteoclast activity is reduced, but osteoblast stimulation and new bone formation are insufficient
Solution Approach 1:
The invention shifts focus from the catabolic side (osteoclast inhibition) to the anabolic side (osteoblast stimulation). By targeting sclerostin, a negative regulator of Wnt signaling, the therapy directly activates osteoblast proliferation and differentiation through enhanced Wnt pathway activity, rather than indirectly preserving bone by suppressing osteoclasts.
Solution Approach 2:
Sclerostin acts as an intermediary molecule that bridges the gap between therapeutic intervention and osteoblast activation. The compound binds to sclerostin to prevent it from inhibiting LRP5/6 receptors, thereby allowing Wnt ligands to effectively stimulate osteoblast activity without directly acting on osteoblasts themselves.
3Productivity
If demineralized bone matrix is used for bone growth, then some endogenous growth factors remain, but disease transmission risk and bacterial contamination risk exist
Solution Approach 1:
The invention replaces complex biological materials like demineralized bone matrix with a small molecule compound (Sclerostin antibody or FPP analogs) that can be synthesized, sterilized, and administered without disease transmission risks. The small molecule approach eliminates the need for cadaveric or allogeneic tissue sources while maintaining therapeutic efficacy through targeted Wnt pathway activation.
Solution Approach 2:
The invention substitutes a biochemical approach (small molecule or antibody therapy) for a mechanical/biological approach (bone matrix grafting). Instead of relying on physical bone material containing endogenous growth factors, the therapy uses pharmacological modulation of the Wnt pathway to stimulate bone formation, eliminating contamination risks associated with tissue processing and storage.
4Productivity
If PTH and BMP agonists are used to increase bone mineral, then bone formation is stimulated, but systemic disease treatment has not progressed beyond Phase I trials
Solution Approach 1:
The invention enables localized delivery of Wnt pathway activation at the bone defect site using small molecule compounds or antibodies with favorable pharmacokinetic properties. This localized approach avoids the systemic side effects that have limited PTH and BMP agonists, allowing progression to later clinical trial phases by treating the local bone formation problem without widespread systemic disruption.
Solution Approach 2:
The invention changes the molecular target from PTH receptors or BMP receptors to sclerostin, a circulating inhibitor of Wnt signaling. This parameter change in target selection allows for more favorable dosing regimens and fewer systemic side effects compared to PTH analogs, facilitating advancement through clinical trial phases while maintaining effective bone formation stimulation.
Data Source
Figure 1
AI summary
In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes, bone loss, and cancer, using a compound of Formula I.